コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 adenosine receptors, dopamine receptor, and sphingosine 1-phosphate receptor.
2 contrasting with the proposed access for the sphingosine 1-phosphate receptor.
3 from chemokine receptors, integrins, and the sphingosine-1-phosphate receptor.
4 of activation-induced cytidine deaminase and sphingosine-1-phosphate receptor.
5 s such as vasa, pumilio and piwi, as well as sphingosine-1-phosphate receptor.
6 d apoptosis was independent of activation of sphingosine 1-phosphate receptors.
7 n and mouse S1P(5) gene products as encoding sphingosine 1-phosphate receptors.
8 d maturation by activating G protein-coupled sphingosine 1-phosphate receptors.
9 er cell apoptosis in a manner independent of sphingosine-1-phosphate receptors.
10 extramedullary tissues into lymph depends on sphingosine-1-phosphate receptors.
11 ndent "transactivation" of G protein-coupled sphingosine-1-phosphate receptors.
12 ation of surface-expressed G protein-coupled sphingosine-1-phosphate receptors.
13 signals mediated by chemokine, integrin, and sphingosine-1-phosphate receptors.
14 to optimize the oral exposure of a series of sphingosine 1-phosphate receptor 1 (S1P(1)) antagonists
26 ves a malicious amplification loop involving sphingosine 1-phosphate receptor 1 and the NF-kappaB/IL-
27 red mice maintains significantly higher lung sphingosine 1-phosphate receptor 1 expression compared w
29 ere, we present the crystal structure of the sphingosine 1-phosphate receptor 1 fused to T4-lysozyme
30 ave important implications for targeting the sphingosine 1-phosphate receptor 1 in solid organ transp
32 r-promoting agent that effectively maintains sphingosine 1-phosphate receptor 1 levels and improves o
34 FTY720 (S)-phosphonate maintains endothelial sphingosine 1-phosphate receptor 1 protein expression in
35 FTY720 is a high-affinity agonist at the sphingosine 1-phosphate receptor 1 that prevents lymphoc
36 e does not induce beta-arrestin recruitment, sphingosine 1-phosphate receptor 1 ubiquitination, and p
38 ed these observations to confirm that S1PR1 (sphingosine 1-phosphate receptor 1) and integrin beta4 (
39 he cell surface and consequent activation of sphingosine 1-phosphate receptor 1, Src and Fyn tyrosine
42 CD62L and beta7-integrin, yet expression of sphingosine-1 phosphate receptor 1 (which is a critical
45 g a newly characterized potent and selective sphingosine-1-phosphate receptor 1 (S1P) agonist with ph
47 nic lymphocyte accumulation involved reduced sphingosine-1-phosphate receptor 1 (S1P1) expression and
49 ly activates the promoters of both CD62L and sphingosine-1-phosphate receptor 1 (S1P1), whose express
55 of thymus-exiting and skin-homing molecules sphingosine-1-phosphate receptor 1 and CCR10 and accumul
57 novel immunomodulator FTY720 down-modulates sphingosine-1-phosphate receptor 1 on lymphocytes at low
58 r Rac1 and Rac2 in transducing chemokine and sphingosine-1-phosphate receptor 1 signals leading to mo
60 nanomolar concentrations, thereby inhibiting sphingosine-1-phosphate receptor 1-dependent egress of l
62 enitor cells (NSCs) in vitro via a PAR1-PAR3-sphingosine-1-phosphate-receptor 1-Akt pathway, which su
65 the beta2 adrenergic receptor (beta2AR), the sphingosine 1-phosphate receptor-1 (S1P1), or the kappa-
70 lial sphingosine 1-phosphate signals through sphingosine 1-phosphate receptor-1 to prevent mitochondr
71 use they down-regulate the expression of the sphingosine-1 phosphate receptor-1, which mediates the e
72 was required for effective transcription of sphingosine-1-phosphate receptor-1 (S1P(1)) and CD62L in
73 have identified cortical sinuses as sites of sphingosine-1-phosphate receptor-1 (S1P(1))-dependent T-
75 We have shown that transgenic expression of sphingosine-1-phosphate receptor-1 (S1P1) in immature th
77 ible mouse model with a temporally disrupted sphingosine-1-phosphate receptor-1 (S1PR1) gene specific
79 cular B-cell egress via the marginal zone is sphingosine-1-phosphate receptor-1 (S1PR1)-dependent.
80 the sphingosine kinase-1 inhibitor, and the sphingosine-1-phosphate receptor-1/-3 antagonist VPC2301
81 inhibit PP2A and that FTY720-P, acting as a sphingosine-1-phosphate-receptor-1 agonist, elicits sign
82 amily (expressed in HEK293 cells) identified sphingosine-1-phosphate receptor 2 (S1P(2) ) as being ac
83 neutralizing anti-S1P antibody (mAb) and the sphingosine-1-phosphate receptor 2 (S1PR2) antagonist JT
89 ere more resistant but became dispersed when sphingosine-1-phosphate receptor-2 was also removed.
90 in the aPC pathway were fully compensated by sphingosine 1 phosphate receptor 3 (S1P3) deficiency or
96 emokine receptors (CXCR1, CXCR2, and CXCR4), sphingosine 1-phosphate receptor-3 (S1P3), the melanocor
98 significantly upregulated the expression of sphingosine-1-phosphate receptor 4 on neutrophils, and t
99 Duane NK cells have a 30-fold deficiency in sphingosine-1-phosphate receptor 5 (S1P5) transcript lev
100 strongly support a cardioprotective role for sphingosine-1-phosphate receptor activation during MI.
104 With this objective in mind, we used the sphingosine-1 phosphate receptor agonist fingolimod, a d
106 /HI administration of FTY720 (fingolimod), a sphingosine-1-phosphate receptor agonist that blocks lym
107 Mice lacking MZ B cells, or treated with a sphingosine-1-phosphate receptor agonist to dislocate th
108 eatment with sphingosine-1-phosphate or SEW (sphingosine-1-phosphate receptor agonist) remained effec
110 ral lymph nodes (LN) by direct activation of sphingosine 1-phosphate receptors, along with the partic
115 that expression of CD69, by interfering with sphingosine-1-phosphate receptor function, is a critical
116 his comparative characterization of multiple sphingosine-1-phosphate receptor genes and their spatiot
118 nase inhibitor N, N-dimethylsphingosine or a sphingosine 1 phosphate receptor inhibitor VPC23019 on i
119 oring in patients with multiple sclerosis on sphingosine 1-phosphate receptor modulating agents.
123 onist or antagonist effects on select LPA or sphingosine 1-phosphate receptors, nor did they inhibit
124 matory sites by decreasing expression of the sphingosine-1 phosphate receptor normally required for e
127 rapid recruitment (5 minutes) to CEMs of the sphingosine 1-phosphate receptor (S1P(1)), the serine/th
130 ed phosphorylation of, the barrier-promoting sphingosine 1-phosphate receptor (S1P1) within caveolin-
131 phate (S1P) is the endogenous ligand for the sphingosine 1-phosphate receptors (S1P1-5) and evokes a
133 m, fingolimod-phosphate (fingolimod-P), is a sphingosine 1-phosphate receptor (S1PR) modulator that i
135 as 5-fold greater selectivity for binding to sphingosine-1-phosphate receptor (S1PR) 1 (S1PR(1)) vers
136 cent data have demonstrated the potential of sphingosine-1-phosphate receptor (S1PR) agonism in the t
137 termine the impact of fingolimod (FTY720), a sphingosine-1-phosphate receptor (S1PR) agonist, on 2 mo
139 iated through S1P binding to specific GPCRs [sphingosine-1-phosphate receptor (S1PR)1-5] and some oth
140 thymus through transcriptional activation of sphingosine-1-phosphate receptor S1pr1 as well as for na
143 ific protease activated receptors (PARs) and sphingosine-1-phosphate receptors (S1PRs), in that siRNA
146 These results indicate that FTY720- and sphingosine 1-phosphate receptor-stimulated T cell migra
147 in-mediated cell growth and survival via the sphingosine 1-phosphate receptor subtype 2 (S1P2) follow
148 in a straightforward total synthesis of the sphingosine 1-phosphate receptor-subtype 1 (S1P(1)) agon
149 Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that i
150 ta demonstrate that Edg-8 is a high affinity sphingosine 1-phosphate receptor that couples to G(i/o)a
151 The capacity of drugs that act on type 1 sphingosine 1-phosphate receptors to suppress organ graf
154 us probing is followed by entry dependent on sphingosine 1-phosphate receptor type 1, capture of cell
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。